Xcout IntelSign inSubscribe

Asep Medical Holdings Inc.

SEPSFBiotechVictoria, Canada

Asep Medical Holdings Inc., operating primarily through its subsidiary ASEP Medical Inc., is dedicated to advancing both a rapid diagnostic system for Sepsis and a range of peptide-based therapeutic treatments applicable across various medical conditions. The company, initially incorporated in 2020 under the name Trenchant Life Sciences Investment Corp., later rebranded to its present title, Asep Medical Holdings Inc. Its corporate base of operations is located in Vancouver, Canada.

Subscribe to see Asep Medical Holdings Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

Asep Medical Holdings Inc. at a glance

Asep Medical Holdings Inc. is a biotech company headquartered in Victoria, Canada. It is publicly listed (SEPSF) with a market capitalisation of $173,021. Xcout tracks 11 named people at Asep Medical Holdings Inc., including Richard Heinzl (Interim CEO & Chairman of the Board).

As of 16 November 2026. Source: Xcout Intel.

Industry
Biotech
Headquarters
Victoria, Canada
Market cap
$173,021
Employees
6
Ticker
SEPSF

Asep Medical Holdings Inc. leadership

  • Richard HeinzlInterim CEO & Chairman of the Board
  • Dr. Richard HeinzlInterim chief Executive Officer, board member
  • Jacqueline Tucker FCPAChief Financial Officer
  • Jacqueline M. TuckerChief Financial Officer
  • Fadia SaadChief Business Development Officer
  • Evan HaneyChief Scientific Officer

5 more named people on record for Asep Medical Holdings Inc., with roles, board committees and tenure — see the full roster →

Asep Medical Holdings Inc. competitors

A few of Asep Medical Holdings Inc.'s closest competitors — see the full list of competitors and alternatives →

AXIM BIOTECHNOLOGIES, INC.AXIM · BiotechSan Diego, CA, United States
62% matchPublic

AXIM Biotechnologies, Inc. specializes in the creation and distribution of advanced diagnostic solutions for healthcare, focusing on critical areas such as SARS-CoV-2 (COVID-19), ocular health, and cancer treatment. The company is currently developing rapid diagnostic assays that quantify functional neutralizing antibodies, which are essential for preventing the SARS-CoV-2 virus from attaching to human cells. Additionally, it offers serological diagnostic tests designed to detect neutralizing antibodies, thereby assessing the body's adaptive immune response to the virus, and is developing tests to identify inflammation biomarkers for the effective management of COVID-19 patients. For eye health, AXIM is pioneering quick, quantitative tear tests to measure Matrix metalloproteinase-9, an inflammatory marker associated with dry eye disease. In its oncology pipeline, the firm is advancing SBI-183, an anti-metastatic compound engineered to inhibit tumor cell growth and block the spread of cancer, as well as SPX-1009, another anti-metastatic therapy aimed at determining the levels of quiescin sulfhydryl oxidase I. Established in 2010, the company was formerly known as Axim International Inc. before officially changing its name to AXIM Biotechnologies, Inc. in July 2014, and it is headquartered in San Diego, California.

Market cap$1M
Employees6
AXIM BIOTECHNOLOGIES, INC. competitors & alternatives →
Aptorum Group LimitedAPM · BiotechPrinceton, United Kingdom
62% matchPublic

Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. In addition, it is developing NLS-1, which is in preclinical trial for the treatment of endometriosis; DLS-1+2, which is in preclinical trial to treat NSCLC with mutation; DLS-3, which is in preclinical trial to treat autoimmune disease; CLS-1, a macromolecule, which is in preclinical trial to treat obesity; and CLS-1 and CLS-3. Further, the company offers NativusWell DOI (NLS-2), a dietary supplement for women undergoing menopause; and provides management services. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

Market cap$5.2M
Employees1
Aptorum Group Limited competitors & alternatives →

Get Asep Medical Holdings Inc.'s news by email

Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.

Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →

Something wrong or missing about Asep Medical Holdings Inc.? Suggest a correction · Work at Asep Medical Holdings Inc.? Claim this profile

Is this your company? Add the Xcout Intel badge to your website

Free, for any company on Xcout Intel. It links visitors to this profile.

Asep Medical Holdings Inc. on Xcout Intel

Share this card

Post the link and the card appears automatically — each network fetches the image itself.

Asep Medical Holdings Inc. — share card preview

Instagram, TikTok and Slack canvases don't expand links — download the card as a PNG and post it as an image instead.

More on Asep Medical Holdings Inc. in Xcout Intel

  • 11 named people with titles, LinkedIn and board committees
  • The full competitor set, tracking, exports and API access
Subscribe to Xcout Intel →